NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinson’s Disease
informed today that it was awarded a grant of
Foundation for Parkinson’s Research. These funds will support the next
clinical study with ND0611, a new dermal patch for the treatment of
Parkinson’s disease, as part of the Foundation’s prestigious Clinical
Intervention Awards 2010 program. This study will evaluate the safety,
tolerability, levodopa pharmacokinetics, and possible clinical benefits of
ND0611 in advanced Parkinson’s disease patients.
ND0611 is a proprietary drug formula that enables, for the first time,
the continuous administration of carbidopa via a sub-cutaneous dermal patch.
Carbidopa is conventionally administered orally with levodopa to prevent its
breakdown. In pre-clinical studies, plasma levodopa concentration profiles
showed markedly less fluctuation after continuous administration of ND0611.
The levodopa area-under-the-curve values and trough concentrations were
greatly increased when ND0611 was administered together with standard
levodopa products (Sinemet(R), Stalevo(R) and Sinemet(R) CR). This effect was
achieved through an as-yet unclear mode of action that may involve a novel
levodopa metabolic pathway. Subcutaneous carbidopa delivery may permit more
continuous levels of levodopa to be maintained in the brain, thus helping to
manage motor fluctuations in Parkinson’s disease patients.
“The enormous show of confidence by The Michael J. Fox Foundation for
Parkinson’s Research in this new therapeutic approach for Parkinson’s disease
strengthens our efforts to develop innovative treatments for the many unmet
needs of patients with this disorder,” said
NeuroDerm’s Chairman and CEO. “It also underscores NeuroDerm’s deep
commitment and expertise in the development of novel therapeutics for
diseases of the central nervous system.”
NeuroDerm is an emerging pharmaceutical company that develops novel
therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm’s
technology is based on proprietary reformulations of well established oral
drugs, whose low bio-availability is the major impediment to better efficacy.
The company’s lead product is ND0611, a revolutionary skin patch for the
treatment of Parkinson’s disease. Other products for the treatment of various
diseases, including ADD, ADHD, schizophrenia and Alzheimer’s disease, are in
different stages of development. NeuroDerm is headquartered in the Weizmann
Science Park, Ness Ziona,
Contact: Oded S. Lieberman, PhD MBA, Chairman & CEO email@example.com Tel.: +972-8-946 2729; Cell: +1-617-517 6077
SOURCE NeuroDerm Ltd